Sanofi’s SuliquaTM combination therapy approved in European Union

Sanofi (NYSE:SNY) said today that the European Commission granted marketing authorization in Europe for its SuliquaTM combination product for adults with type II diabetes. The therapy is a fixed-ratio combination of basal insulin glargine and lixisenatide, intended to be used with metformin to improve patients’ glycemic control.

Suliqua will be available in 2 pre-filled SoloSTAR pens at different dosage levels to address the insulin needs of individual patients, Sanofi reported. The 10–40 pen will deliver 10-40 dose steps of insulin glargine at 100 Units/mL with 5-20 micrograms of lixisenatide. The 2nd pen will deliver 30-60 dose steps of insulin glargine in combination with 10-20 micrograms of lixisenatide.

Get the full story at our sister site, Drug Delivery Business News.

The post Sanofi’s SuliquaTM combination therapy approved in European Union appeared first on MassDevice.

from MassDevice http://ift.tt/2iRz7Pp